- Last Updated on 07 January 2013
- Published on 21 December 2012
Initial treatment options for patients with multiple myeloma in Australia have significantly expanded with the recent PBS listing of Velcade (bortezomib) for both transplant-eligible and transplant-ineligible patients, in combination with chemotherapy.
Philadelphia chromosome-positive chronic myeloid lukaemia (Ph+ CML)
Australian patients can now access Tasigna (nilotinib) on the PBS, for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid lukaemia (Ph+ CML) in chronic phase. Tasigna is a 2nd generation tyrosine kinase inhibitor (TKI) and is a potent selective inhibitor of Bcr-Abl. Data comparing Tasigna with the 1st generation Glivec (imatinib) shows a more rapid and deeper molecular response and a decreased rate of progression to accelerated or blast phase CML.